Last reviewed · How we verify
Intranasal Oxytocin
At a glance
| Generic name | Intranasal Oxytocin |
|---|---|
| Also known as | Syntocinon, Syntocinon spray, Pitocin, Syntocinon Spray, Oxytocin intranasally |
| Sponsor | Evdokia Anagnostou |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oxytocin to Treat PTSD (PHASE2)
- Oxytocin Effects on Bone in Children With Autism Spectrum Disorder (PHASE2)
- Understanding Cognition, Oxytocin & Pain in Elders (PHASE2, PHASE3)
- Oxytocin's Effects on Emotional Processing and Its Acting Routes (NA)
- Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain (PHASE2, PHASE3)
- The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain (NA)
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal Oxytocin CI brief — competitive landscape report
- Intranasal Oxytocin updates RSS · CI watch RSS
- Evdokia Anagnostou portfolio CI